Dianthus Therapeutics, Inc. (NASDAQ:DNTH – Get Free Report) saw a large growth in short interest in the month of August. As of August 15th, there was short interest totalling 4,060,000 shares, a growth of 10.9% from the July 31st total of 3,660,000 shares. Currently, 20.2% of the company’s shares are sold short. Based on an average daily volume of 271,200 shares, the days-to-cover ratio is currently 15.0 days.
Dianthus Therapeutics Stock Performance
DNTH traded down $1.18 during trading on Tuesday, hitting $27.65. The stock had a trading volume of 139,519 shares, compared to its average volume of 189,833. The stock has a 50 day simple moving average of $27.79 and a two-hundred day simple moving average of $25.89. Dianthus Therapeutics has a twelve month low of $6.58 and a twelve month high of $33.77. The company has a market capitalization of $811.53 million, a PE ratio of -4.74 and a beta of 1.89.
Dianthus Therapeutics (NASDAQ:DNTH – Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.51) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.50) by ($0.01). Dianthus Therapeutics had a negative return on equity of 21.03% and a negative net margin of 1,376.42%. The business had revenue of $1.86 million during the quarter, compared to analyst estimates of $0.63 million. On average, equities research analysts anticipate that Dianthus Therapeutics will post -2.32 EPS for the current year.
Wall Street Analysts Forecast Growth
View Our Latest Stock Report on Dianthus Therapeutics
Institutional Trading of Dianthus Therapeutics
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bain Capital Life Sciences Investors LLC acquired a new stake in shares of Dianthus Therapeutics during the first quarter worth about $89,761,000. RA Capital Management L.P. acquired a new stake in Dianthus Therapeutics during the 1st quarter valued at approximately $69,990,000. Vanguard Group Inc. boosted its holdings in shares of Dianthus Therapeutics by 250.0% in the 1st quarter. Vanguard Group Inc. now owns 537,828 shares of the company’s stock valued at $16,135,000 after acquiring an additional 384,182 shares during the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Dianthus Therapeutics in the first quarter worth $11,251,000. Finally, Vestal Point Capital LP purchased a new position in shares of Dianthus Therapeutics during the fourth quarter worth $1,404,000. Institutional investors and hedge funds own 47.53% of the company’s stock.
Dianthus Therapeutics Company Profile
Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.
Further Reading
- Five stocks we like better than Dianthus Therapeutics
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- 3 Small Cap Stocks That Insiders Are Buying
- With Risk Tolerance, One Size Does Not Fit All
- Analysts Forecast Big Upside for Western Digital—Don’t Miss Out
- Best Aerospace Stocks Investing
- 3 Must-Own Stocks for Bullish Investors in Today’s Market
Receive News & Ratings for Dianthus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dianthus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.